RxDoctor Payments Data

Diego Alvarez, MD

Internal Medicine · Oneida, NYNPI 1780661488

Payments from drug & device makers

$4,204in general payments, 2019–2025

Across 273 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$653
  • Novo Nordisk$580
  • Boehringer Ingelheim$343
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$302
  • Novartis$155
  • plus $586 from 13 others

What the payments were for

  • Food & beverage$4,198100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,204 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$48,009
Medicare patients
79
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$149,601
Trelegy ElliptaFluticasone/Umeclidin/Vilanter121$124,873
EliquisApixaban46$53,844
FarxigaDapagliflozin Propanediol30$34,070
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$24,298
SymbicortBudesonide/Formoterol Fumarate44$23,590
Spiriva RespimatTiotropium Bromide21$19,950
JanuviaSitagliptin Phosphate16$19,170
Arnuity ElliptaFluticasone Furoate25$7,729
Incruse ElliptaUmeclidinium Bromide12$7,517
Albuterol Sulfate HfaAlbuterol Sulfate159$7,494
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$5,487
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,324
BreynaBudesonide/Formoterol Fumarate11$3,873
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$3,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$580$149,601117 claims
GSKTrelegy Ellipta, Arnuity Ellipta, Incruse Ellipta$1,586$140,119158 claims
AstraZenecaFarxiga, Symbicort$653$57,65974 claims
PfizerEliquis$39$53,84446 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$343$25,27432 claims
MerckJanuvia$43$19,17016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Oneida

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →